Another day and another morning with an opening spike in large cap biotechs that was immediately sold. This is a disturbing pattern and one that needs to break if the sector is going to continue to move higher. Until we can get follow through on these opening moves, we are going to at best treat […]
Catalyst Watch – Vol. 2, Edition 34 (12/5/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: The company […]
December 4 Biotech Update
A blah start to the trading day. There are not a particularly large numbers of movers and the market seems for the most part to be drifting. As such, it is difficult to discern any real trend outside of chop. So it seems like the market and sector are searching for a direction. I would […]
December 3 Biotech Update
It is a basically neutral day in the market but the sector seems a little weak but this is off of a good day yesterday. One problem to keep an eye on is that many of the stocks I follow start very strong but weaken throughout the day. I would certainly prefer to stop seeing […]
Quick Note on GWPH
GWPH has been on one huge rollercoaster. After climbing back from $61 in mid-October to $80 in late November, it has given up 15% in just the last 3 trading days, falling back to $68 as the rest of biotech surges following their morning Q3 conference call. Perhaps investors had been expecting more detailed data […]
December 1 Bitoech Update
Markets are weak and the biotech sector is moving with it and it appears that small cap and momentum plays are being most affected (large caps seem to be holding up fairly well). The market probably needs to consolidate its recent move as do a lot of biotechs but the wild cards this month are […]
November 26 Biotech Update
The trading is winding down as we approach Thanksgiving and I suspect today is going to be slow and get slower. The market will be open again on Friday but will likely be even slower as many will likely take the half trading day off. I suspect this also means that news flow will also […]
Quick Survery
We are constantly looking for was to improve Chimera and ensure that everyone is getting value for their money. As part of this process, we are looking for feedback from you all. Please take the time to fill out this quick survey, so we can learn where we need to improve and what you find […]
November 24 Biotech Update
A decent start to the week but volume is going to be low all week and I suspect that will increase the chop. So I would not read anything into the broader sector outside of this week having a slight positive bias. That being said, we do have to respect any move that is done […]
What to Look For at ASH 2014
The year is nearly over, though it feels like scientific conferences never end. December 6th marks the last big Cancer meeting of the year- then we turn the page to 2015. We’ve put together a list of over a dozen companies presenting at ASH, along with data we believe investors will be looking for: AGIO […]
November 21 Biotech Update
A great open for the market but then it immediately proceeded to lay an egg. It is still early and the key is going to be how it responds to the selling. The only worrying sign is that the downdraft really seemed to hit biotechs and these have been a leading indicator of larger market […]
Catalyst Watch – Vol. 2, Edition 33 (11/20/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: The company […]
November 20 Biotech Update
Market starts a little weak this morning and generally is taking the sector with it. That being said it is not a rout by any means, so it seems like there sector is looking to find its footing before the next move. Luckily we have some news to talk about. 1. EPZM reported very positive […]
November 19 Biotech Update
A weak start to the morning both in the broader market and biotech sector and this is on the back of a good day yesterday. It just reinforces the view that the market seems to have almost no memory from day to day. Luckily we have some interesting data to talk about. 1. The talk […]
November 17 Biotech Update
This morning was just a little bit busy. The market was neutral, which gives us a nice clean way to see how the biotechs are reacting to news. In general, it appears that good news is still moving stocks higher, although some of the moves were more muted than you would expect. In any case, […]
November 14 Biotech Update
The markets are fine this morning but biotech is weak and seems to be led lower by GILD and other large caps. As long as GILD is weak it is going to be difficult for the sector to lead and this could eventually spill over into the broader markets. We have quickly moved from extremes […]
November 13 Biotech Update
A decent start to the market with biotech generally participating. GILD seems to remain the odd stock and continues to struggle at these levels for reasons that I will follow up on tomorrow. Sentiment seems to be changing in GILD and we certainly need to keep an eye on it even if you do not […]
November 12 Biotech Update
A weaker start to the day today but I still see this as the market treading water as opposed to a new trend. I certainly would keep an eye on the action of the small caps as they have been an early warning signal and they too seem to be treading water with some winners […]
November 10 Biotech Update
News continues to roll in and the market is providing a relatively neutral backdrop, which gives us a good sense of what the price action means. In other words, the price action of biotech stocks after news seems to be a clear signal of market reaction and is not being cloudy by macro effects. This […]
November 7 Biotech Update
To say it has been a busy day is an understatement. Rather than try and cover everything that is happening, I would prefer to focus on a couple items a day. I would also note that the sector seems weakening which is probably an early signal for the broader market but it is difficult to […]
